Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 202

1.

Anti-BCMA CAR T-Cell Therapy in Multiple Myeloma.

Quintás-Cardama A.

N Engl J Med. 2019 Jul 18;381(3):e6. doi: 10.1056/NEJMc1907520. No abstract available.

PMID:
31314981
2.

Synthetic T cell receptor-based lymphocytes for cancer therapy.

Getts D, Hofmeister R, Quintás-Cardama A.

Adv Drug Deliv Rev. 2019 Feb 15;141:47-54. doi: 10.1016/j.addr.2019.04.002. Epub 2019 Apr 12. Review.

PMID:
30981835
3.

What CAR Will Win the CD19 Race?

Quintás-Cardama A.

Mol Cancer Ther. 2019 Mar;18(3):498-506. doi: 10.1158/1535-7163.MCT-18-1070. Review.

PMID:
30824581
4.

CD19 directed CARs in acute lymphoblastic leukemia: state of the art and beyond.

Quintás-Cardama A.

Leuk Lymphoma. 2019 May;60(5):1346-1348. doi: 10.1080/10428194.2018.1533132. Epub 2019 Jan 16. No abstract available.

PMID:
30646790
5.

CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma.

Quintás-Cardama A.

Oncotarget. 2018 Jul 6;9(52):29843-29844. doi: 10.18632/oncotarget.25688. eCollection 2018 Jul 6. No abstract available.

6.

CAR T-Cell Therapy in Large B-Cell Lymphoma.

Quintás-Cardama A.

N Engl J Med. 2018 Mar 15;378(11):1065. doi: 10.1056/NEJMc1800913. No abstract available.

PMID:
29542306
7.

p53 pathway dysfunction in AML: beyond TP53 mutations.

Post SM, Kornblau SM, Quintás-Cardama A.

Oncotarget. 2017 Nov 27;8(65):108288-108289. doi: 10.18632/oncotarget.22713. eCollection 2017 Dec 12. No abstract available.

8.

Tumorigenesis promotes Mdm4-S overexpression.

Pant V, Larsson CA, Aryal N, Xiong S, You MJ, Quintas-Cardama A, Lozano G.

Oncotarget. 2017 Apr 18;8(16):25837-25847. doi: 10.18632/oncotarget.15552.

9.

p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.

Quintás-Cardama A, Hu C, Qutub A, Qiu YH, Zhang X, Post SM, Zhang N, Coombes K, Kornblau SM.

Leukemia. 2017 Jun;31(6):1296-1305. doi: 10.1038/leu.2016.350. Epub 2016 Nov 25.

PMID:
27885271
10.

Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Short NJ, Benton CB, Chen HC, Qiu P, Gu L, Pierce S, Brandt M, Maiti A, Min TL, Naqvi K, Quintas-Cardama A, Konopleva M, Kadia T, Cortes J, Garcia-Manero G, Ravandi F, Jabbour E, Kantarjian H, Andreeff M.

Am J Hematol. 2016 Dec;91(12):1221-1226. doi: 10.1002/ajh.24500. Epub 2016 Aug 29.

11.

p53-independent ibrutinib responses in an Eμ-TCL1 mouse model demonstrates efficacy in high-risk CLL.

Lee HJ, Gallardo M, Ma H, Zhang X, Larsson CA, Mejia A, Hornbaker MJ, Qi Y, Su X, Pageon LR, Quintas-Cardama A, Post SM.

Blood Cancer J. 2016 Jun 10;6:e434. doi: 10.1038/bcj.2016.41.

12.

hnRNP K Is a Haploinsufficient Tumor Suppressor that Regulates Proliferation and Differentiation Programs in Hematologic Malignancies.

Gallardo M, Lee HJ, Zhang X, Bueso-Ramos C, Pageon LR, McArthur M, Multani A, Nazha A, Manshouri T, Parker-Thornburg J, Rapado I, Quintas-Cardama A, Kornblau SM, Martinez-Lopez J, Post SM.

Cancer Cell. 2015 Oct 12;28(4):486-499. doi: 10.1016/j.ccell.2015.09.001. Epub 2015 Sep 24.

13.

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase.

Hughes TP, Saglio G, Quintás-Cardama A, Mauro MJ, Kim DW, Lipton JH, Bradley-Garelik MB, Ukropec J, Hochhaus A.

Leukemia. 2015 Sep;29(9):1832-8. doi: 10.1038/leu.2015.168. Epub 2015 Jun 29.

14.

Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.

Quintás-Cardama A, Zhang N, Qiu YH, Post S, Creighton CJ, Cortes J, Coombes KR, Kornblau SM.

Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):115-127.e15. doi: 10.1016/j.clml.2014.07.011. Epub 2014 Aug 12.

15.

Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib.

Olshen A, Tang M, Cortes J, Gonen M, Hughes T, Branford S, Quintás-Cardama A, Michor F.

Haematologica. 2014 Nov;99(11):1701-9. doi: 10.3324/haematol.2013.085977. Epub 2014 Sep 12.

16.

Loss of the novel tumour suppressor and polarity gene Trim62 (Dear1) synergizes with oncogenic Ras in invasive lung cancer.

Quintás-Cardama A, Post SM, Solis LM, Xiong S, Yang P, Chen N, Wistuba II, Killary AM, Lozano G.

J Pathol. 2014 Sep;234(1):108-19. doi: 10.1002/path.4385. Epub 2014 Jul 16.

17.

A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Quintás-Cardama A, Daver N, Kim H, Dinardo C, Jabbour E, Kadia T, Borthakur G, Pierce S, Shan J, Cardenas-Turanzas M, Cortes J, Ravandi F, Wierda W, Estrov Z, Faderl S, Wei Y, Kantarjian H, Garcia-Manero G.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):401-10. doi: 10.1016/j.clml.2014.03.001. Epub 2014 May 6.

18.

Bullet 'manicure': does lead prevent hydroxyurea-induced cutaneous toxicity?

Falchi L, Quintás-Cardama A.

Jpn J Clin Oncol. 2014 May;44(5):512. doi: 10.1093/jjco/hyu011. No abstract available.

19.

Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.

Yoshimura M, Ishizawa J, Ruvolo V, Dilip A, Quintás-Cardama A, McDonnell TJ, Neelapu SS, Kwak LW, Shacham S, Kauffman M, Tabe Y, Yokoo M, Kimura S, Andreeff M, Kojima K.

Cancer Sci. 2014 Jul;105(7):795-801. doi: 10.1111/cas.12430. Epub 2014 Jun 3.

20.

Nilotinib.

Ostendorf BN, le Coutre P, Kim TD, Quintás-Cardama A.

Recent Results Cancer Res. 2014;201:67-80. doi: 10.1007/978-3-642-54490-3_3. Review.

PMID:
24756785
21.

Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy.

Quintás-Cardama A, Choi S, Kantarjian H, Jabbour E, Huang X, Cortes J.

Clin Lymphoma Myeloma Leuk. 2014 Aug;14(4):327-334.e8. doi: 10.1016/j.clml.2014.01.003. Epub 2014 Jan 15.

22.

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.

Gibbons DL, Pricl S, Posocco P, Laurini E, Fermeglia M, Sun H, Talpaz M, Donato N, Quintás-Cardama A.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3550-5. doi: 10.1073/pnas.1321173111. Epub 2014 Feb 18.

23.

Ponatinib in Philadelphia chromosome-positive leukemias.

Quintas-Cardama A.

N Engl J Med. 2014 Feb 6;370(6):577. doi: 10.1056/NEJMc1315234. No abstract available.

PMID:
24499222
24.

Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics.

Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):163-71. doi: 10.1016/j.clml.2013.07.009. Epub 2014 Jan 22.

25.

Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.

Verstovsek S, Gotlib J, Gupta V, Atallah E, Mascarenhas J, Quintas-Cardama A, Sun W, Sarlis NJ, Sandor V, Levy RS, Kantarjian HM, Mesa RA.

Onco Targets Ther. 2013 Dec 17;7:13-21. doi: 10.2147/OTT.S53348. eCollection 2013.

26.

Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.

Ohanian M, Kantarjian HM, Quintas-Cardama A, Jabbour E, Abruzzo L, Verstovsek S, Borthakur G, Ravandi F, Garcia-Manero G, Champlin R, Pierce S, Alattar ML, Trinh LX, Luthra R, Ferrajoli A, Kadia T, O'Brien S, Cortes JE.

Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):155-162.e1. doi: 10.1016/j.clml.2013.08.008. Epub 2013 Dec 9.

27.

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.

Strati P, Kantarjian H, Thomas D, O'Brien S, Konoplev S, Jorgensen JL, Luthra R, Abruzzo L, Jabbour E, Quintas-Cardama A, Borthakur G, Faderl S, Ravandi F, Cortes J.

Cancer. 2014 Feb 1;120(3):373-80. doi: 10.1002/cncr.28433. Epub 2013 Oct 22.

28.

Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials.

Yilmaz M, Kantarjian H, Jabbour E, O'Brien S, Borthakur G, Verstovsek S, Garcia-Manero G, Ravandi F, Burger J, Pierce S, Quintas-Cardama A, Cortes J.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):693-9. doi: 10.1016/j.clml.2013.05.011. Epub 2013 Sep 20.

29.

Detection of dormant chronic myeloid leukemia clones in the bone marrow of patients in complete molecular remission.

Quintás-Cardama A, Grgurevic S, Rozovski U, Li P, Estrov Z, Cortes J.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):681-5. doi: 10.1016/j.clml.2013.07.010. Epub 2013 Sep 20.

30.

The p53-Mdm2 feedback loop protects against DNA damage by inhibiting p53 activity but is dispensable for p53 stability, development, and longevity.

Pant V, Xiong S, Jackson JG, Post SM, Abbas HA, Quintás-Cardama A, Hamir AN, Lozano G.

Genes Dev. 2013 Sep 1;27(17):1857-67. doi: 10.1101/gad.227249.113. Epub 2013 Aug 23.

31.

Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia.

Strati P, Daver N, Ravandi F, Pemmaraju N, Pierce S, Garcia-Manero G, Nazha A, Kadia T, Jabbour E, Borthakur G, Faderl S, Quintas-Cardama A, Kantarjian H, Cortes J.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S276-81. doi: 10.1016/j.clml.2013.05.020. Epub 2013 Aug 19.

32.

Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience.

Benjamini O, Kantarjian H, Rios MB, Jabbour E, O'Brien S, Jain P, Cardenas-Turanzas M, Faderl S, Garcia-Manero G, Ravandi F, Borthakur G, Quintas-Cardama A, Cortes J.

Leuk Lymphoma. 2014 Dec;55(12):2879-86. doi: 10.3109/10428194.2013.831092. Epub 2013 Sep 10.

33.

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti D.

Blood. 2013 Sep 12;122(11):1923-34. doi: 10.1182/blood-2013-03-492181. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 8;123(19):3056.

34.

Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.

Falchi L, Kantarjian HM, Wang X, Verma D, Quintás-Cardama A, O'Brien S, Jabbour EJ, Ravandi-Kashani F, Borthakur G, Garcia-Manero G, Verstovsek S, Burger JA, Luthra R, Cortes JE.

Am J Hematol. 2013 Dec;88(12):1024-9. doi: 10.1002/ajh.23560. Epub 2013 Sep 12.

35.

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia.

Daver N, Shastri A, Kadia T, Quintas-Cardama A, Jabbour E, Konopleva M, O'Brien S, Pierce S, Zhou L, Cortes J, Kantarjian H, Verstovsek S.

Leuk Res. 2013 Nov;37(11):1440-4. doi: 10.1016/j.leukres.2013.07.007. Epub 2013 Jul 25.

36.

Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.

Nazha A, Kantarjian H, Cortes J, Quintás-Cardama A.

Expert Opin Pharmacother. 2013 Oct;14(14):1977-86. doi: 10.1517/14656566.2013.821464. Epub 2013 Jul 23. Review.

PMID:
23875628
37.

Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments.

Laurini E, Posocco P, Fermeglia M, Gibbons DL, Quintás-Cardama A, Pricl S.

Mol Oncol. 2013 Oct;7(5):968-75. doi: 10.1016/j.molonc.2013.06.001. Epub 2013 Jun 15.

38.

Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months.

Nazha A, Kantarjian H, Jain P, Romo C, Jabbour E, Quintas-Cardama A, Luthra R, Abruzzo L, Borthakur G, Ravandi F, Pierce S, O'Brien S, Cortes J.

Haematologica. 2013 Nov;98(11):1686-8. doi: 10.3324/haematol.2013.090282. Epub 2013 Jun 28.

39.

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S.

Blood. 2013 Aug 8;122(6):893-901. doi: 10.1182/blood-2012-07-442012. Epub 2013 Jun 19.

40.

Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia.

Eghtedar A, Kantarjian H, Jabbour E, O'Brien S, Burton E, Garcia-Manero G, Verstovsek S, Ravandi F, Borthakur G, Konopleva M, Quintas-Cardama A, Cortes J.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):477-84. doi: 10.1016/j.clml.2013.02.025. Epub 2013 Jun 14.

41.

Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.

Daver N, Liu Dumlao T, Ravandi F, Pierce S, Borthakur G, Pemmaraju N, Nazha A, Faderl S, Jabbour E, Garcia-Manero G, Cortes J, Kantarjian H, Quintás-Cardama A.

Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):435-40. doi: 10.1016/j.clml.2013.02.021. Epub 2013 Jun 10.

42.

The changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.

Larsson CA, Cote G, Quintás-Cardama A.

Mol Cancer Res. 2013 Aug;11(8):815-27. doi: 10.1158/1541-7786.MCR-12-0695. Epub 2013 May 3. Review.

43.

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities.

Jain P, Kantarjian H, Nazha A, O'Brien S, Jabbour E, Romo CG, Pierce S, Cardenas-Turanzas M, Verstovsek S, Borthakur G, Ravandi F, Quintás-Cardama A, Cortes J.

Blood. 2013 Jun 13;121(24):4867-74. doi: 10.1182/blood-2013-03-490128. Epub 2013 Apr 25.

44.

Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia.

Kantarjian HM, Martinelli G, Jabbour EJ, Quintás-Cardama A, Ando K, Bay JO, Wei A, Gröpper S, Papayannidis C, Owen K, Pike L, Schmitt N, Stockman PK, Giagounidis A; SPARK-AML1 Investigators.

Cancer. 2013 Jul 15;119(14):2611-9. doi: 10.1002/cncr.28113. Epub 2013 Apr 19.

45.

Prognostic impact of RAS mutations in patients with myelodysplastic syndrome.

Al-Kali A, Quintás-Cardama A, Luthra R, Bueso-Ramos C, Pierce S, Kadia T, Borthakur G, Estrov Z, Jabbour E, Faderl S, Ravandi F, Cortes J, Tefferi A, Kantarjian H, Garcia-Manero G.

Am J Hematol. 2013 May;88(5):365-9. doi: 10.1002/ajh.23410. Epub 2013 Mar 20.

46.

Significance of cytogenetic abnormalities in patients with polycythemia vera.

Sever M, Quintás-Cardama A, Pierce S, Zhou L, Kantarjian H, Verstovsek S.

Leuk Lymphoma. 2013 Dec;54(12):2667-70. doi: 10.3109/10428194.2013.784970. Epub 2013 Apr 17.

47.

Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance.

Quintás-Cardama A, Verstovsek S.

Clin Cancer Res. 2013 Apr 15;19(8):1933-40. doi: 10.1158/1078-0432.CCR-12-0284. Epub 2013 Feb 13. Review.

48.

Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.

Quintás-Cardama A, Kantarjian H, Pierce S, Cortes J, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):315-318.e2. doi: 10.1016/j.clml.2013.01.001. Epub 2013 Feb 4.

49.

Considerations for early switch to nilotinib or dasatinib in patients with chronic myeloid leukemia with inadequate response to first-line imatinib.

Quintás-Cardama A, Jabbour EJ.

Leuk Res. 2013 May;37(5):487-95. doi: 10.1016/j.leukres.2013.01.006. Epub 2013 Feb 4. Review.

PMID:
23391518
50.

The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure.

Jabbour E, Kantarjian H, Ghanem H, O'Brien S, Quintas-Cardama A, Garcia-Manero G, Cardenas M, Cortes J.

Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):302-6. doi: 10.1016/j.clml.2012.12.005. Epub 2013 Jan 12.

Supplemental Content

Loading ...
Support Center